pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Antisense Oligonucleotide (ASO) · news · pharmadog
← back to Antisense Oligonucleotide (ASO)
News · Antisense Oligonucleotide (ASO)
26
stories
3d
Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win
fiercebiotech
4d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
4d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
9d
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
biospace
11d
Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?
biospace
14d
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
biospace
18d
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
21d
Ionis' top scientist Frank Bennett to retire; Recursion selects its first AI chief
endpoints
22d
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
22d
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
biopharma dive
24d
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
biospace
25d
RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC
fiercebiotech
25d
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
Jul 22, 26
Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug
fiercebiotech
Jul 22, 26
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
biospace
Jul 20, 26
Genetic medicine luminaries launch new center for personalized therapies
fiercebiotech
Jul 9, 26
Roche scraps two Ionis-partnered Huntington’s drugs
biopharma dive
Jul 9, 26
Updated: AstraZeneca sinks on unexpected heart drug trial failure
endpoints
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 18, 26
Kardigan extends biotech’s streak of big IPOs with $400M haul
biopharma dive
Jun 11, 26
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
biopharma dive
Jun 10, 26
Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundation
endpoints
Jun 4, 26
STAT+: AI titans push Congress for DNA safeguards
stat
May 28, 26
GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’
biopharma dive
May 14, 26
Biogen pushing tau drug forward despite Alzheimer’s study failure
biopharma dive
Dec 22, 25
Fierce Biotech Fundraising Tracker '26: Abcuro secures $66M; InduPro assembles $77M
fiercebiotech
